RecruitingNCT05403710

Botulinum Toxin Therapy in Hidradenitis Suppurativa

Targeting Nociceptors in Hidradenitis Suppurativa

Sponsor

University of Massachusetts, Worcester

Enrollment

20 participants

Start Date

Jun 7, 2022

Study Type

OBSERVATIONAL

Conditions

Hidradenitis Suppurativa Hyperhidrosis

Summary

This study will build on data from mice and humans implicating TRPV1 nociceptors in the pathogenesis of the type-17 chronic inflammatory skin disease Hidradenitis Suppurativa (HS). In this study, the investigators will test the hypothesis that inhibiting neuropeptide activity with botulinum toxin reduces pathogenic inflammation.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Botulinum toxin for people with hidradenitis suppurativa and hyperhidrosis. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGBotulinum toxin

Administration of botulinum toxin (50 units/100cm2 injected intradermally) into lesional skin

Locations(1)

University of Massachusetts Chan Medical School

Worcester, Massachusetts, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05403710

Related Trials

A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa

NCT0692185018 locations

A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)

NCT0688819314 locations

An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS

NCT076654374 locations

A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy

NCT05889182285 locations

Myriad™ Augmented Soft Tissue Reconstruction Registry

NCT0524396615 locations